Bloomberg reported on Friday that the UK drugmaker, GlaxoSmithKline, is in deliberations to sell a part of its portfolio of antibiotics, however, there is ‘no certainty’ that this will lead to a transaction.
The sale could reportedly bring in ‘several hundreds of million dollars,’ with the company cashing out on drug products that generate about $200m (€179m) in annual revenue.
The company recently announced plans to separate out its consumer health business from its core operations under a ‘transformation plan’, which would also include the slimming down of its vaccines business, including the cutting of 935 jobs in Belgium.
The ‘new GSK’ that will be formed following that separation will see it focus on R&D operations, particularly on immunology, genetics and new technologies, while concurrently increasing its investments in R&D and the launch of new products.
In February, the company also proceeded with the sale of 15 of its consumer healthcare products to generic drugmaker Stada for over €300m.